EGFR and non-small cell lung carcinoma: In addition, the combination of MK2206 with the anti-EGFR monoclonal antibody cetuximab in cetuximab-resistant NSCLC cells decreased the activity of both AKT and MAPK, thus highlighting the importance of simultaneous pathway inhibition [21].